News

Collaboration aims to help in the development of more robust, scalable vaccine manufacturing processes.

Company has announced the launch of its FastChain service to meet increasing need for speed & flexibility in global clinical trials.

Company has announced that the study of REOLYSIN® in combination with FOLFOX6 bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer metastatic to the liver is now active.

Collaboration aims to employ powerful new approaches for the determination of high-resolution X-ray structures of GPCRs to discover new drug lead compounds.

Company has announced that Evotec has selected Genedata Screener® as a data management platform solution for its drug discovery research.

Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.

Acquisition combines Blue Stream with Charles River’s existing discovery, safety assessment, and biologics capabilities creates a leading provider with the ability to support biologic and biosimilar development from characterization through clinical testing and commercialization.

Sartorius has announced the acquisition of U.S. based IntelliCyt Corporation, an award-winning innovator and manufacturer of novel cell screening platforms used in drug discovery.

The study will evaluate the safety and efficacy of the combination of BL-8040 and KEYTRUDA®, MSD’s anti-PD-1 therapy, in up to 30 subjects with metastatic pancreatic cancer.

Company has received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine to prevent infection from this concerning virus.